natgillin/translations-raw huggingface dataset:
A peptide as claimed in claims 1 to 8, for use in treating diabetes (Type I and/or Type II), excess bodyweight, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poorly regulated food intake. 
Peptid sukladno patentnim zahtjevima 1 do 8, naznačen time, da se koristi za liječenje dijabetesa (tip I 1 /1li tip Il), višak tjelesne težine, prekomjerne konzumacije hrane, metaboličkog sindroma, reumatoidnog artritisa, bezalkoholna bolest masne jetre, osteoporoze, ili osteoartritisa 1 u slučajevima lošije razine glukoze u krvi, lošijih reguliran odgovor na testove tolerancije glukoze, ili slabo reguliran unos hrane.
Aaa is an amino acid residue selected from Ser, Asn or Thr; wherein a C-terminus thereof is a free terminus, is amidated or is esterified. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je Aaa aminokiselinski ostatak, kojeg se bira između Ser i Thr; gdje je C-kraj slobodni kraj.
a heavy chain comprising, according to Kabat, the CDR-H1 of the sequence SEQ ID No. 
antitijelo koje sadrži: – laki lanac koji prema IMGT sadrži CDR-L1 sekvencije SEQ ID No.
The holder according to claim 1, wherein the bolt is able to be fixed at different separation distances from the guide in dependence on the radius of the employed tube. 
Držač prema patentnom zahtjevu 2, naznačen time, da se vijak (72, 72') ili klin može biti pričvršćen uz različite separacijske razmake od vodilice (40) u ovisnosti o polumjeru zauzetog tuljca.
In another aspect the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of atherosclerosis by changing the composition of the plaques to reduce the risk of plaque rupture and atherothrombotic events. 
Upotreba spoja formule (I) kako je definirano u bilo kojem zahtjevu 1 do 10, ili njegove farmaceutski prihvatljive soli, naznačena time, da se navedeni spoj upotrebljava za proizvodnju lijeka za liječenje ili profilaksu ateroskleroze pomoću promjene sastava plakova, u svrhu smanjenja rizika od pucanja plaka i pojave aterotrombotskih događaja.
An antibody or antigen-binding fragment thereof according to claim 3 wherein the heavy chain and/or the light chain comprise in their frameworks one or several of the following amino acid residues, and in particular all the following amino acid residues at positions identified with respect to Kabat numbering: 
Antitijelo ili njegov antigen-vezujući fragment u skladu s patentnim zahtjevom 3, naznačeno time što težak lanac i/ili lak lanac sadrže u svojim okvirima jedan ili više od slijedećih aminokiselinskih ostataka, i naročito sve sljedeće aminokiselinske ostatke na položajima identificiranim u odnosu na Kabat numeraciju:
is independently selected from hydrogen, C1-10alkyl, C3-10cycloalkyl, C6-10aryl, a 4- to 12-membered heteroaryl or 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryl and heterocyclyl may be optionally substituted with one or more R24a's and the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, S, or O; 
je nezavisno odabrano od vodik, C1-10alkil, C3-10cikloalkil, C6-10aril, 4- do 12-člani heteroaril ili 4- do 12-člani heterociklil, gdje alkil, aril, heteroaril i heterociklil mogu po izboru biti supstituirani sa jednim ili više R24a i heteroaril i heterociklil se sastoje od ugljikovih atoma i 1, 2, 3, ili 4 heteroatoma nezavisno odabranih iz grupe koja se sastoji od N, S, ili O;
The method according to claim 2, wherein in the compound represented by the formula (1) or a pharmaceutically acceptable salt thereof m represents 2; l and n respectively represent 1; X represents —CH2—; 
Spoj predstavljen formulom (1) ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 2, naznačen time, da R1 predstavlja vodik, C1-C6 alkilnu skupinu, hidroksi- C1-C6 alkilnu skupinu, benzilnu skupinu ili tri- C1-C6 alkilsililoksi- C1-C6 alkilnu skupinu; i R4 predstavlja bilo koju od
Further embodiments of the invention encompass: 
Datum objave europske prijave patenta:
contacting the sample comprising DNA with a primer pair, which when used in a nucleic acid amplification reaction with genomic DNA from corn plant MON89034, produces an amplicon comprising SEQ ID NO:1 or SEQ ID NO:2; and 
(a) miješanje uzorka koji sadrži DNA sa parom začetnica, koji kada se koristi u reakciji amplifikacije nukleinske kiseline s genomskom DNA iz biljke kukuruza MON89034, proizvodi amplikon koji sadrži SEQ ID NO: 1 ili SEQID NO: 2; 1
generating surface data which indicates a surface shape of the master model of the interior and exterior members from the acquired three-dimensional data; 
generiranja podataka o površini (36) koji ukazuju na oblik površine glavnog modela (14) unutarnjih i vanjskih dijelova (4) iz dobivenih trodimenzijskih podataka;
The compound of Paragraph 25, wherein R41 is selected from the group consisting of -H, lower alkyl, lower alkoxy, lower cycloalkyl, and lower cycloalkoxy. 
Spoj prema zahtjevu 19, pri čemu je R, izabran iz skupine koju čine -H, niži alkil, niži alkoksi, niži cikloalkil i niži cikloalkoksi.
A method of controlling undesirable vegetation at a locus which comprises diluting with water a herbicidal composition according to any one of claims 1 to 13 and applying a weed controlling amount of the diluted composition to the locus. 
Postupak za kontrolu neželjene vegetacije na lokusu naznačen time da se sastoji od razrjeđivanja s vodom herbicidnog pripravka prema bilo kojem zahtjevu od 1 do 13 i primjenu razrijeđenog pripravka u količini za kontroliranje korova na lokus.
A method according to Paragraph 1 wherein the temperature is set at 36.5±0.2°C. A method according to Paragraph 1 wherein the temperature is set at 36.5°C. A method of culturing heterologous protein-secreting mammalian cells in a cell culture supernatant wherein the cell culture supernatant is maintained at a pH that is set at X±0.05 wherein X has a value of from 7.15 to 7.20, with the proviso that the pH is set at greater than 7.10. 
Postupak uzgoja sisavačkih stanica koje izlučuju heterologni protein u supernatantu kulture stanica, naznačen time što se supernatant kulture stanica održava na pH podešenom na X + 0,05, gdje X ima vrijednost od 7,15 do 7,20, uz uvjet da je pH podešen na vrijednost veću od 7,10, gdje je kultura stanica kontinuirana kultura koju se održava uz gustoću od 1,4 x 105 do 2,8 x 105 stanica/ml.
Sample hygroscopicity was tested by H2O content determination before the test and after 24 hours maintenance at 100% humidity (keeping in a closed vessel over water). 
Higroskopnost uzorka ispitana je pomoću utvrđivanja sadržaja H2O prije ispitivanja i nakon držanja 24 sata pri 100%-tnoj vlazi (držanje u zatvorenoj posudi iznad vode).
Compound according to Claim 1, characterized in that X1 and X2 are, independently of one another, an alkyl group having from 1 to 4 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 3 carbon atoms or one or more alkoxy groups having 1 or 2 carbon atoms. 
Spoj prema zahtjevu 1, naznačen time, da su X1 i X2 međusobno neovisno alkil-skupina koja ima od jednoga do četiri atoma ugljika, i koja je opcijski supstituirana s jednom ili više alkil-skupina koje imaju od jednoga do tri atoma ugljika ili s jednom ili više alkoksi-skupina s jednim ili dva atoma ugljika.
Furthermore, both Isomer C and Isomer B are potent inhibitors of the serotonin transporter protein SERT. 
Nadalje, oba, Izomer C i Izomer B su snažni inhibitori serotonin transporter proteina SERT.
The reaction mixture was poured into water (500 mL) and extracted with ethyl acetate. 
Reakcijska smjesa se prelije preko vode (500 ml) i ekstrahira sa etil acetatom.
The process according to claim 6, wherein the basifying agent is selected from the group consisting of basic hydroxides, alkoxides and/or basic ammonium compounds. 
Postupak prema zahtjevu 6, naznačen time, da se lužnato sredstvo odabire iz skupine koju čine: bazični hidroksidi, alkoksidi 1/ili bazični amonijevi spojevi.
Hence, compounds XXII can be transformed into compounds XVII under the conditions described for compounds XVII. 
Dalje se spojevi XXII mogu transformirati u spojeve XVII u uvjetima opisanima za spojeve XVII.
The jar of the invention is more quickly and reliably used with heavy duty wirelines, that has been possible in the prior art. 
Udarac prema izumu se brže i pouzdanije koristi s jakim žicanim vezama, koje su bile moguće i do sada prema postojećem stanju tehnike.
at least one second transformer arrangement with a primary side connectable to a second AC network (550b; 650b; 750b; 850b; 950b) and with a secondary side, at least one second converter unit (540b; 640b; 740c,d; 840c,d; 940c) connected to the secondary side of the second transformer arrangement, wherein the first and second converter units are interconnected by means of a DC connection (560, 562; 660, 662; 760, 762, 764; 860, 862; 960, 962), characterized in that at least parts of both the first and the second transformer arrangement are integrated in one physical transformer unit (530a-c; 630a-f; 730a-f; 830a-f; 930a-f), within a common transformer casing, wherein two separate transformer cores are provided within the transformer casing. 
najmanje jedan drugi sklop transformatora s primarnom stranom koja se može spojiti na drugu AC mrežu (550b; 650b; 750b; 850b; 950b) 1 sa sekundarnom stranom, - < najmanje jednu drugu pretvaračku jedinicu (540b; 640b; 740c,d; 840c,d; 940c) spojenu na sekundarnu stranu sklopa drugog transformatora, pri čemu su prva i druga pretvaračka jedinica međusobno spojene pomoću DC spoja (560, 562; 660, 662; 760, 762, 764; 860, 862; 960, 962), naznačen time što su barem dijelovi i prvog i drugog sklopa transformatora integrirani u jednu fizičku transformatorsku jedinicu (530a-c; 630a-f; 730a-f; 830a-f; 930a-f), unutar zajedničkog kućišta transformatora, pri čemu su unutar kućišta transformatora predviđene dvije odvojene jezgre transformatora.
A method according to claims 24 or 25, wherein at least part of the compound of at least one element of group IVB of the periodic table is on a sulphate or sulphide form. 
Metoda u skladu s patentnim zahtjevima 24 ili 25, pri čemu je barem dio tvari tvar barem jednog elementa grupe IVB periodičkog sustava u obliku sulfata ili sulfita.
Ar is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl, wherein aryl is a 5- to 14-membered monocyclic, bicyclic or tricyclic aromatic ring system; and heteroaryl is an aromatic heterocycle ring of 5 to 14 members having at least one heteroatom selected from nitrogen, oxygen and sulfur, containing at least 1 carbon atom, including monocyclic, bicyclic, and tricyclic ring systems, 
GN u kojoj Ar je odabran iz skupine koju čine: aril, supstituirani aril, heteroaril i supstituirani heteroaril, pri čemu je aril 5-člani do 14-člani monociklički, biciklički ili triciklički aromatski sustav prstena; i heteroaril je aromatski heterociklički prsten od 5 do 14 članova, koji ima najmanje jedan heteroatom odabran od dušika, kisika i sumpora, te sadrži najmanje jedan
The infuser for alcoholic beverages according to claim 5, characterized by the fact that the pump (4) is peristaltic. 
Infuzor u skladu s patentnim zahtjevom 1, naznačen time što je crpka (4) peristaltička.
Co-administration of tolperisone decreased the IC50 value of dextromethorphan by about 75% (IC50 of dextromethorphan alone: 1.56 µM; dextromethorphan in the presence of 25 µM tolperisone: 0.38 µM), i.e. 
Istovremeno davanje tolperisona smanjuje vrijednost ICsg dekstrometorfana za približno 75% (ICsa samog dekstrometorfana: 1,56 uM; dekstrometorfan u prisutnosti 25 uM tolperisona: 0,38 uMj), tj.
or unsubstituted or substituted naphthyl or quinolyl, wherein the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, alkyl, haloalkyl, alkylthio, haloalkylthio, arylthio, alkoxy, haloalkoxy, alkylcarbonyl, haloalkylcarbonyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, alkylamino, di(alkyl)amino; 
Rgje vodik, alkil, alkoksialkil, alkilkarbonil, alkiltiokarbonil ili nesupstituirani ili supstituirani benzil, gdje supstituenti mogu biti svaki neovisan jedan od drugoga i odabrani su iz skupine koja se sastoji od sljedećih: cijano, nitro, halogen, alkil, haloalkil, alkiltio, haloalkiltio, ariltio, alkoksi, haloalkoksi, alkilkarbonil, haloalkilkarbonil, alkilsulfinil, haloalkilsulfinil, alkilsulfonil, haloalkilsulfonil, alkilamino, di(alkil)amino;
The dark mixture was diluted with water (200 mL) and extracted with ethyl acetate. 
Tamna smjesa se razrijedi s vodom (200 ml) i ekstrahira s etil acetatom.
For ideal melting of the melt layer it is possible to use additional substances that absorb energy, preferably additional substances that absorb light and/or radiation and/or heat, e.g. laser pigments, mineral fillers and metal particles. 
Rubna traka prema jednom od prethodnih zahtjeva naznačena time što su za optimalnu apsorpciju unesene energije plazme, laserskog zračenja ili vrelog zraka, u sloj taljevine dodani pigmenti i dodatne tvari, koje apsorbiraju energiju, poželjno svijetlo i/ili zračenje kao 1 mineralna punila ili metalne čestice.
Further, compounds of the present invention are useful in the inhibition of the production of free fatty acids while resulting in substantially lower or in some instances no measurable flushing side effects, which effects are commonly associated with the administration of niacin. 
Nadalje, spojevi prikazanog izuma su korisni u inhibiciji produkcije slobodnih masnih Kiselina uz bitno niže ili u nekim slučajevima potpuno bez mjerljivih nuz djelovanja crvenila, koja su uobičajeno povezana s primjenom niacina.
A is selected from -C(B)- and N; 
A je odabran od iN;
The second embodiment of the first aspect of the method comprises the step of: 
(33) Država ili organizacija podnošenja prve prijave: SE 1250007
A compound according to claim 1, wherein A is optionally substituted heterocycloalkyl or optionally substituted heterocycloalkenyl. 
Spoj prema zahtjevu 1, naznačen time da je A po izboru supstituirani heterocikloalkil ili po izboru supstituirani heterocikloalkenil.
and R9 are independently H, -L-W, or C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted with halo, amino, hydroxyl, alkoxy or cyano; or R8 and R9 together with the atoms to which they are attached may form a ring; 
R* i R? su neovisno H, -L-W ili Cigalkil, Co galkenil ili Co galkinil, od kojih svaki može biti opcijski supstituiran sa sljedećima: halogen, amino, hidroksil, alkoksi ili cijano; ili RÅ i R? zajedno s atomima na koje su priključeni, mogu tvoriti prsten;
In this model serum LH is high (about 20× fold higher than with intact rats, due to the absence of the negative feedback of testicular testosterone). 
U ovom modelu LH u serumu je visok (približno 20 x viši nego kod normalnih štakora, zbog nedostatka negativne povratne veze od strane testosterona iz testisa).
The antibody or fragment thereof of claim 1, wherein the antibody is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fd, Fv, dAb, F(ab′)2, scFv, bispecific single chain Fv dimers, diabodies, triabodies and scFv genetically fused to the same or a different antibody. 
Protutijelo ili njegov fragment sukladno bilo kojem od patentnih zahtjeva 1 do 18, naznačeno time da, je to protutijelo odabrano iz skupine: monovalentnog protutijela, protutijela pune dužine, fragmenta protutijela odabranog iz skupine koja sadrži Fab, Fab', Fab'-SH, Fd, Fv, F(ab')2, scFv, bispecifične dimere Fv jednostrukog lanca, diatijela, triatijela i scFv genetski fuzijski stopljene na isto ili drugačije antitelo.
Produced by Streptomyces hygroscopicus, rapamycin has been shown to possess a number of valuable pharmacological attributes. 
Rapamicin, koji nastaje u Streptomyces hygroscopicus, posjeduje razna vrijedna farmakološka svojstva.
In one embodiment, the artificial T cell receptor of the invention comprises the amino acid sequence according to SEQ ID NO: 46 or a fragment thereof, or a variant of said amino acid sequence or fragment. 
Umjetni T stanični receptor sukladno bilo kojem od patentnih zahtjeva 6 do 10, koji sadrži aminokiselinsku sekvencu sukladno SEK ID BR: 46.
The crystalline dihydrogenphosphate salt monohydrate of the present invention has a phase purity of at least about 5% of the form with the above X-ray powder diffraction, fluorine-19 MAS NMR, carbon-13 CPMAS NMR, and DSC physical characteristics. 
Kristalni monohidrat dihidrogenfosfatne soli predmetnog izuma ima faznu čistoću od najmanje oko 5% oblika sa gore opisanim karakteristikama rendgenske difrakcije praška, fluorin-19 MAS NMR-a, ugljik-13 CPMAS NMR-a, i DSC.
to 10 Insoluble, non selective, non digestible oligosaccharide 
3 do 10 Neopljivi, neselektivni, neprobavljivi oligosaharid
The method of claim 7, wherein nucleic acid encoding the anti-VEGF antibody or the anti-VEGF antibody fragment is selected from the group consisting of the nucleic acid sequence comprising SEQ ID NO: 33 and the nucleic acid sequence comprising SEQ ID NO:34. 
SEK.:47. Postupak prema patentnom zahtjevu 7, naznačen time, da je nukleinska kiselina koja kodira anti- VEGE protutijelo ili fragment anti-VEGF protutijela odabrana iz skupine koju čine nukleinskokiselinska sekvenca ID BR.
The stable aqueous aldehyde solution according to claim 1 wherein the pH modifier comprises at least one component selected from the group consisting of: potassium hydroxide, sodium hydroxide, sodium phosphate and sodium bicarbonate. 
Stabilna vodena otopina aldehida u skladu s bilo kojim od patentnih zahtjeva 1 do 6 pri čemu modifikator pH obuhvaća najmanje jedno od sljedećih: kalijev hidroksid, natrijev hidroksid, natrijev fosfat 1 natrijev bikarbonat.
entropy-decoding (S1410) the encoded residual signals to generate quantized coefficient information; 
entropijsko dekodiranje (S1410) kodiranih rezidualnih signala kako bi se generirale informacije o kvantiziranom koeficijentu;
In one embodiment, E represents a bond. 
E predstavlja vezu, - (CR?
Preparation of Uncooked Mass 
Priprema nekuhane mase
The organic extracts were combined and dried over anhydrous magnesium sulphate and after filtration the solvent was removed at reduced pressure to afford a yellow oil (9 g). 
Organski ekstrakti se spoje i suše iznad anhidridnog magnezij sulfata 1 nakon filtriranja se otapalo ukloni uz smanjeni tlak da bi se dobilo žuto ulje (9 g).
Microcrystalline cellulose: 10.0-500.0 mg and optionally coated with coating film comprising opacizer, plasticizer and colouring agent. 
- < mikrokristalnu celulozu: 10.0-500.0 mg i proizvoljno je obložen s premazom filma koji sadržava sredstvo za postizanje neprozirnosti, plastifikator i bojilo.
Example 2 Production of Aggregated Conformation Prion Protein As a first experiment, the starting liquid composition contained 5% vol/vol of the Protease K-resistant prion protein Sc237 BH, representing an aggregated conformation prion protein which is known to induce amplification of the aggregated conformation in the native conformation shNBH, was admixed with a 10% wt/vol preparation of hamster prion protein shNBH (Syrian hamster normal brain homogenate) having the native conformation, which was produced by homogenization of brain tissue detergent containing aqueous buffer solutions. 
Postupak proizvodnje prionskog proteina agregirane konformacije iz prionskog proteina nativne konformacije putem dovođenja proteina priona nativne konformacije u kontakt s prionskim proteinom agregirane konformacije u tekućem sastavu i podvrgavanje tekućeg sastava barem jednom ciklusu koji se sastoji od generiranja sile smicanja i faze odmora, naznačeno time da se sila smicanja primjenjuje na svaki element volumena tekućeg sastava 1 sastoji se od jedne uniformne jačine sile smicanja s intenzitetom raspona od maksimalno 10% vrijednosti sile smicanja.
In a preferred embodiment of formula (2-a) R1 is hydrogen or a nitrogen protecting group selected from pivaloyl and t-butyloxycarbonyl (BOC). 
Spoj prema zahtjevu 60, naznačen time, da u formuli (2-a), RI je vodikova ili dušikova zaštitna skupina odabrana od pivaloila i t-butiloksikarbonila (BOC).
The term addition salt also comprises the solvates which the disclosed componds, as well as the salts thereof, are able to form. 
Pojam adicijska sol također uključuje solvate koje opisani spojevi, kao i njihove soli, mogu tvoriti.
4 shows the system of FIG. 2 in a state, in which a capsule has reached its closing position between a bell member and the capsule holder, 
Slika 4 prikazuje sustav iz slike 2 u položaju u kojemu je čahura postigla svoj zatvoreni položaj između zvonastog elementa i držača čahure,
In one embodiment, R2 and R3 combine with the nitrogen to which they are attached to form optionally substituted pyrrolo. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se R* i R* kombiniraju s ugljikom na kojeg su vezani kako bi tvorili izborno supstituirani morfolinil.
The mixture was filtered, dried with MgSO4 and concentrated in vacuo to give 5.05 g 2-allylsulfanyl-benzylamine (28.2 mmol, 91%). 
Smjesa se filtrira, suši s MgSO, 1 koncentrira in vacuo kako bi se dobilo 5.05 g 2-alilsulfanil-benzilamina (28.2 mmol, 91%).
The rounding at the introduction end of the tube is preferably designed in such a manner that the plane of the central sampling opening extends perpendicular to the centre line of the sampler. 
Poželjno je da je zaobljenje na kraju cijevi koja se uvodi izvedeno na takav način da se ravnina središnjeg otvora za uzimanje uzorka prostire okomito na središnju liniju naprave za uzimanje uzorka.
a tear strength property of from 26.3 to 78.8 N/mm in accordance with ASTM procedure D-1938; and a DIN abrasion of from 5 to 31 mm3 in accordance with ASTM procedure D-5963. 
svojstvo jačine trganja od oko 26.3 do 78.8 N/mm u skladu s ASTM postupkom D-1938; i DIN abrazija od oko 5 do 31 mm3 u skladu s ASTM postupkom D-5963.
and a second polypeptide chain has a structure represented by the formula: VH2-L3-VH1-L4-CH1 [II] 
VLi-Li-VLeLo-CL_ [1] i drugi polipeptidni lanac ima strukturu predstavljenu s formulom: Vin-La-Vry-L4-Cru [II] pri čemu:
Four patients received the dose of 40 mg. 
Četiri su pacijenta dobili dozu od 40 mg.
The method according to Disclosure 43, wherein the disorder is selected from a proliferative disorder, cancer, an inflammatory disorder, an autoimmune disorder, a viral infection, an ophthalmological disorder, a neurodegenerative disorder, a disorder of abnormal tissue growth, a disorder related to food intake, an allergy, and a respiratory disorder. 
Spoj za uporabu prema zahtjevu 13, naznačen time što je poremećaj odabran od proliferativnog poremećaja, raka, upalnog poremećaja, autoimunog poremećaja, virusne infekcije, oftalmološkog poremećaja, neurodegenerativnog poremećaja, poremećaja abnormalnog rasta tkiva, poremećaja vezanog uz unos hrane, alergije, te respiratornog poremećaja.
forming the glass. 
(1ii) Formiranje stakla.
A compound according to claim 1 for use in the treatment of benign prostate hyperplasia. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da je hiper-proliferativni poremećaj benigna hiperplazija prostate.
The system of any of the preceding claims wherein the system is configured to provide a predictive acceleration of the vehicle and issue a control signal before the vehicle (2) exceeds the location-based imposed speed limit. 
Sustav prema bilo kojem od prethodnih zahtjeva naznačen time što je sustav konfiguriran tako da osigurava predviđajuće ubrzanje vozila i izdaje kontrolni signal prije nego vozilo (2) prijeđe ograničenje brzine nametnuto na temelju lokacije.
The resulting crude is purified by chromatography on silica eluting with iso-hexane/ethyl acetate (0%-20% ethyl acetate) to yield the titled product. 
Dobiveni sirov proizvod se očisti kromatografijom na silika gelu ispirući s izo-heksan/etil acetatom (0%-20% etil acetata), čime se dobije naslovni proizvod.